Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Wall Street is often blamed for reducing corporate managers’ understanding of business to a single, gameable measure of ...

That “waste-to-value” is increasingly getting quiet attention from private equity and infrastructure investors.

Wall Street is still awaiting regulatory approval for the first full-blown private-asset ETFs, but for now opportunistic ...

Trump opened the door for private equity to tap 401(k)s, and now private equity bosses want legal protection. Here's what ...

Private-equity executives entered 2025 with high hopes for a dealmaking recovery that is lifting payouts to fund investors ...

In 2025’s go-go leveraged debt markets, everything is up for negotiation, but a trio of investor protections are proving to ...

Successful firms are increasingly split between behemoths with several business lines and those focusing on their roots of ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

As US navigates a shifting landscape of trade policy under new administration, markets grappling with implications of ...

In 2024, global private equity and venture capital transaction value and volume in biotechnology declined to their lowest ...

As private equity continues to shape the Irish M&A landscape, experts predict strong activity in the coming years, fueled by ...